Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-
based methods being considered the gold standard for drug susceptibility testing, molecular …

Background Drug-resistant tuberculosis (DR-TB) is considered to be a public health threat
and is difficult to cure, requiring a lengthy treatment with potent, potentially toxic drugs. The …

The Comprehensive Resistance Prediction for Tuberculosis: an International Consortium
(CRyPTIC) presents here a data compendium of 12,289 Mycobacterium tuberculosis global …

Background Bedaquiline is a core drug for the treatment of multidrug-resistant tuberculosis;
however, the understanding of resistance mechanisms is poor, which is hampering rapid …

Rationale Bedaquiline has been classified as a group A drug for the treatment of multidrug-
resistant tuberculosis (MDR-TB) by the World Health Organization; however, globally …

Background In 2021, an estimated 4800 people developed rifampicin-resistant tuberculosis
in Mozambique, 75% of which went undiagnosed. Detailed molecular data on rifampicin …

Genomic sequencing has emerged as a powerful tool to enhance early pathogen detection
and characterization with implications for public health and clinical decision making …

Tuberculosis (TB), caused by Mycobacterium tuberculosis, is one of the deadliest infectious
diseases worldwide. Multidrug and extensively drug-resistant strains are making disease …

Antibiotic resistance among bacterial pathogens poses a major global health threat.
Mycobacterium tuberculosis complex (MTBC) is estimated to have the highest resistance …

A total of 1.6 million people died of tuberculosis (TB) in 2021, and approximately 10.6 million
people developed active TB disease due to Mycobacterium tuberculosis complex (MTBC) …